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Abstract:
Background:
Aldose  reductase,  the  first  enzyme  of  the  polyol  pathway,  is  the  key  determinant  for  the  pathogenesis  of  long  term  diabetic
complications. Accordingly, its inhibition represents the major therapeutic strategy to treat this kind of pathologies.
Objectives:
In this work we describe the synthesis and the functional evaluation of a number of spiro-oxazolidinone and spiro-morpholinone
acetic acid derivatives, and their benzyloxy analogs, developed as aldose reductase inhibitors.
Results:
Most of them proved to inhibit the target enzyme, showing IC50 values in the micromolar/low micromolar range. SARs observed
among the three different series allowed to highlight their key pharmacophoric elements, thus creating sound basis for the design of
novel and more effective inhibitors.
Conclusion:
Although  further  substitution  patterns  are  needed,  the  novel  compounds  here  proposed  represent  a  good  starting  point  for  the
development of novel and effective ARIs.
Keywords: Aldose reductase enzyme, Diabetic complications, Spiromorpholinone derivatives, Aldose reductase inhibitors (ARI),
Spiro-oxazolidinones, Spirobenzopyran derivatives, ARL2.
INTRODUCTION
Diabetes mellitus (DM) is one of the most common chronic metabolic disorders, characterized by elevated levels of
blood glucose (hyperglycemia). According to “WHO Global report on diabetes”, the number of people with diabetes
has risen from 108 million in 1980 to 422 million in 2014 [1]. The DM etiopathology is very complex and is closely
related  to  the  onset  of  chronic  complications  such  as  neuropathy,  nephropathy,  cataracts,  retinopathy,  accelerated
atherosclerosis, and increased cardiovascular risk [2]. Therefore, nowadays, this disease is reasonably considered as a
public health issue.
Many studies suggested the inhibition of aldose reductase (ARL2) enzyme as the key therapeutic strategy to prevent
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and/or ameliorate long-term diabetic complications [2]. ARL2 is the first enzyme of the polyol pathway; it is located in
cytosol and it was found in eye lens, retina kidney, adrenal gland and some reproductive organs. ALR2 catalyzes the
NADPH-dependent conversion of glucose to sorbitol, the rate-limiting step of the polyol pathway Fig. (1) [3]; then the
sorbitol produced is converted into fructose by sorbitol dehydrogenase (SDH). Since its hydrophilic nature, this sugar
alcohol does not pass easily through cell membranes, thus accumulating within the cells while being slowly converted
into fructose. The accumulation of sorbitol leads to osmotic stress in cells, event strongly related to the increasing of
NAD+/NADH ratios. As a consequence, an impairment of cellular defense against oxidative injury occurs, leading to
the onset of both micro- and macrovascular complications such as retinopathy, peripheral vascular disease and coronary
artery disease. These events are frequently found in DM and are well known as “complications of secondary diabetes”.
Moreover, many studies demonstrated an ALR2-dependent increase of ROS levels in cells cultured under high glucose
conditions, thus confirming the leading role of this enzyme in the pathogenesis of many diabetic complications [4].
Fig. (1). Polyol pathway of glucose metabolism.
Therefore, ARL2 is considered an interesting target to counteract DM complications. In the last years, many ARL2
inhibitors  (ARI)  have  been  developed  [5,  6]  and  some  of  them  reached  clinical  trials  to  prove  their  efficacy  in
preventing and/or modulating/ameliorating DM complications. The most important ARIs can be classified into two
chemical groups: (a) cyclic imides, such as sorbinil, fidarestat, minalrestat and ranirestat (AS-3201) [7] and (b) acetic
acid derivatives, such as tolrestat, epalrestat, zopolrestat and ponalrestat [8]. To date, only the carboxylic acid epalrestat
is available on the market and used for the treatment of diabetic neuropathy in Japan, India and China [9]. Most of the
ARIs  that  showed  to  be  active  in  in  vitro  tests  failed  the  subsequent  clinical  trials,  mainly  because  of  their
pharmacokinetic drawbacks and, consequently, low in vivo efficacy, besides the onset of adverse side effects. Notably,
the side effects are principally due to the lack of selectivity of ARI toward aldehyde reductase (ALR1, EC 1.1.1.2). This
last enzyme, ALR1, plays a detoxification role in specifically metabolizing toxic aldehydes such as hydroxynonenal
(HNE), 3-deoxyglucosone, and methylglyoxal [10]. Zopolrestat, which belongs to the carboxylic acid derivatives, is
quite selective for ALR2 vs ALR1 and other enzymes. However, the carboxylic class of agents becomes highly protein
bound in vivo thus limiting their efficacy in vivo. On the other hand, ARIs bearing a hydantoin core, including sorbinil,
are relatively non-selective and inhibit ALR1 and ALR2 with comparable efficacies.
Despite being chemically different, ARIs respond to some structural requirements represented by an acidic group,
which  interacts  with  the  anionic  site  of  the  catalytic  site,  and  a  lipophilic  group,  binding  the  hydrophobic  pocket,
necessary for the activity and selectivity towards the enzyme [11].
In a previous work we synthesized new spirobenzopyran derivatives (compounds type A, Fig. 2), as effective ARIs
[12].  The  previously  synthesized  ALR2  inhibitors  possessed  IC50  values  in  the  submicromolar  range  and  a  good
selectivity against the target enzyme.
Starting from these encouraging results, herein we performed a SAR study to investigate the effects on the ARL2
inhibitory activity induced by small structural modifications on the scaffold of type A compounds (Fig. 2).
In particular, we synthesized the analogues with gem-dimethyl group in 2-position of the chromane-scaffold (5-10)
to evaluate the influence of the steric hindrance in this position on the interaction with the active site of the enzyme.
Then, in order to assess the importance of the benzopyran scaffold and the steric effects of substituents in the 2-position
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of the core, we synthesized compounds 11-13, in which the C2-C3 bond of the benzopyran nucleus has been cleaved,
and compounds 5-10, in which the pendant phenyl ring on the benzopyran core has been replaced by gem-dimethyl
groups.
Fig. (2). Medicinal chemistry optimization of spirobenzopyran derivatives.
The new molecules synthesized were evaluated in vitro for their affinity and potency against the target enzyme,
ARL2.
RESULTS AND DISCUSSION
Chemistry
The  acetic  acid  derivatives  3,4  have  been  synthesized  as  reported  in  Scheme  (1).  Briefly,  the  reaction  of
aminoalcohols14,15 [12] and chloroacetyl chloride in a heterogeneous phase yielded the chloroacetamides 16,17 which
were  submitted  to  a  base-catalized  (t-BuOK)  cyclization  to  afford  the  spiromorpholone  derivatives  18,19.  The
subsequent reaction of 18,19 with ethyl bromoacetate and NaH in DMF gave the corresponding esters, which were then
cleaved in high yields to the carboxylic acids 3 and 4, respectively.
Scheme 1. Reagents and Conditions: (a) Chloroacetyl chloride, NaOH, CH2Cl2/H2O, rt, 1 h; (b) t-BuOK, toluene, rt, 3 h; (c) NaH,
ethyl bromoacetate, DMF, N2, 0°C, rt, 1.5 h; (d) KOH, MeOH, reflux, 2 h.
A tandem reaction of spiro-oxazolidinones 22,23 [13] and spiromorpholones 24,25 [14] with ethyl bromoacetate
and the following cleavage of the intermediates (26-29), performed with KOH in MeOH, yielded the carboxylic acids
5-8 as the final products (Scheme 2A).
Spiromorpholine  derivative  30  was  obtained  from 24  by  reduction  with  LiAlH4.  Notably,  to  avoid  the  possible
halogen/metal exchange induced by LiAlH4, the 6-bromide-spiromorpholine 31 was obtained by a selective reduction of
25 [15] performed with a borane-methyl sulfide complex which can tolerate different substituents such as halogens or
nitro-groups [16 - 19]. Subsequently, the reaction of products 30,31 with ethyl bromoacetate in the presence of K2CO3
gave compounds 32,33, which were then cleaved to the corresponding carboxylic acids 9,10 by the use of KOH/MeOH
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mixture (Scheme 2B).
Scheme 2. Reagents and Conditions: (a) Ethyl bromoacetate, NaH, DMF, N2, 0°C, rt,1.5 h; (b) KOH, MeOH, reflux, 2 h; (c) Ethyl
bromoacetate, K2CO3, MeCN, reflux, 12 h.
Compounds  11-13  were  synthesized  starting  from 2-hydroxyacetophenone  and  the  appropriate  benzyl  chloride.
Benzyloxyphenylethanones 34-36 were subjected to a nucleophilic addition with trimethylsilyl cyanide (TMSCN), in
the presence of zinc iodide (ZnI2), to give the corresponding trimethylsilyl cyanohydrins 37-39. The reduction of 37-39,
followed by a cyclization reaction with carbonyl diimidazole (CDI) gave the spirooxalidinone derivatives 43-45, which
were then submitted to the same reaction of alkylation and cleavage above reported for compounds 9,10 to yield the
final products as carboxylic acid 11-13 (Scheme 3).
Scheme 3. Reagents and Conditions: (a) Appropriate methoxybenzyl chloride, KOH, DMSO; rt, 4 h; (b) TMSCN, ZnI2, CH2Cl2, rt, 4
h; (c) LiAlH4, THF, rt, 4 h; (d) CDI, THF, rt, 4 h; (e) Ethyl bromoacetate, n-BuLi, THF, N2, -78 ºC, rt, 12 h; (f) KOH, MeOH, reflux,
2 h.
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Biological Evaluation
Recently, we developed a new class of small molecules bearing a benzopyran scaffold that displayed inhibitory
activity against ARL2, with a high degree of selectivity when compared to the effects induced against ARL1 [12].
Among the previously studied derivatives, compounds 1 (IC50 2.25 μM) and 2 (IC50 0.58 μM), depicted in Fig. (3),
shown the best results in terms of potency against the target enzyme.
Fig. (3). Spirooxazolidine Derivatives 1 and 2.
Previous studies highlighted that the ARL2 inhibition activity was influenced by the presence of both a bromine
atom on the benzopyran scaffold and the substituent in the 2-position of the chromane nucleus. With the aim to extend
the structure-activity relationship (SAR) study of this class of compounds, herein we describe the synthesis of new
molecules,  3-13,  in  which  a  series  of  structural  modifications  have  been  performed  as  following  reported:  (a)
replacement of the spirooxazolidine ring in the core structure of 1 and 2 with a spiromorpholone (derivatives 3 and 4) or
with  a  spiromorpholine  nucleus  (derivatives  9  and  10);  (b)  replacement  of  the  phenyl  ring  in  the  2-position  of  the
benzopyran scaffold  with  small  lipophilic  groups  such as  the  methyl  ones  (derivatives  5-10)  and (c)  change in  the
conformational freedom of spirooxazolidine derivatives 1 and 2 through the cleavage of the C2-C3 bond within the
benzopyran core (derivatives 11-13).
All the synthesized compounds were evaluated for their inhibitory activity against ARL2 and for their selectivity
against aldehyde dehydrogenase (ALR1). Sorbinil, a well-known ARL2 inhibitor characterized by a spiro-chromane
core, was used as the reference standard. Results obtained are reported in (Tables 1 and 2), expressed as IC50 values.
Table 1. ARL2 inhibitory activities of compounds 1-10.
     Compounds      N      Y      X      R      R′      IC50 (μM)
a
     Sorbinil      0.65
     1b      0      CO      H      4-OMe-Ph      H      2.25
     2b      0      CO      Br      4-OMe-Ph      H      0.58
     3      1      CO      H      4-OMe-Ph      Me      n.a.
     4      1      CO      Br      4-OMe-Ph      Me      4.97
     5      0      CO      H      Me      Me      42.3
     6      0      CO      Br      Me      Me      17.3
     7      1      CO      H      Me      Me      2.00
     8      1      CO      Br      Me      Me      n.a.
     9      1      CH2      H      Me      Me      n.a.
     10      1      CH2      Br      Me      Me      4.17
aIC50 values represent the concentration required to produce 50% enzyme inhibition. Standard error of the mean (SEM) is ≤ 10. 
bSee reference [17].
n.a.: not active. No inhibition was observed up to 100 μM of test compounds.
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The synthesized compounds exhibited IC50 values in the micromolar/low micromolar range, with the only exception
of compounds 3, 8 and 9 which proved to be completely inactive.
Noteworthy, results depicted in Table 1 show that the replacement of the spirooxazolidine nucleus of the leads, 1
and 2 [17], with the wider spiromorpholone core, like in compounds 3 and 4, induced a decrease of inhibitory potency
against ARL2. Actually, compound 3, the higher homologue of derivative 1, turned out to be devoid of any inhibitory
activity while compound 4, the higher homologue of 2, showed an almost 8-fold reduction in inhibitory efficacy when
compared to the smaller parent (4, IC50 4.97 vs 2, IC50 0.58 μM).
Table 2. ARL2 inhibitory activities of compounds 10-12.
     Compounds      R      R1      IC50(μM)
a
     Sorbinil      0.65
     11      H      H      4.13
     12      H      OMe      nt
     13      OMe      OMe      3.19
aIC50values represent the concentration required to produce 50% enzyme inhibition. Standard error of the mean (SEM) is ≤ 10. n.t.: not tested.
We then decided to further  investigate the effect  of  the substituent  in the 2-position of  the benzopyran core.  In
particular, we replaced the p-methoxyphenyl ring with a gem-substitution, in which two methyl groups were added.
Regarding  the  spirooxazolidine  series,  this  kind  of  chemical  manipulation  induced  a  significant  decrease  in  the
inhibitory potency of the resulting compounds, 5 and 6, even if the presence of a 6-bromine atom on the chromane core,
like in 6, helped to keep the activity in the low micromolar range (IC50 17.3 μM). On the contrary, the same substitution
pattern on the spiromorpholone series (derivatives 7 and 8) gave rise to contrasting results. Actually, while the gem-
dimethyl substituents conferred a significant inhibitory activity to compound 7 (IC50 2.0 μM), the concomitant presence
of a 6-bromine atom on the chromane core, like in 8, induced a dramatic loss of activity.
With the aim of reducing the conformational restriction of the spiromorpholone derivatives 7 and 8, we synthesized
the spiromorpholine analogs, 9 and 10. This kind of structural modification was able to restore the inhibitory activity of
the  6-bromine  substituted  10  (IC50  =4.17μM).  This  result  let  us  speculate  that  further  improvement  in  the
conformational freedom of this kind of compounds could enhance their inhibitory potency. On this basis, we replaced
the benzopyran scaffold with the more flexible benzyloxy nucleus, thus synthesizing compounds 11-13.
As  reported  in  Table  2,  the  novel  compounds  turned  out  to  be  almost  1.5-fold  less  potent  that  the  parent  1,
demonstrating  that  the  cleavage  of  the  C2-C3 bond of  the  previous  synthesized  compound 1  induced  only  a  slight
decrease of ARL2 inhibitory potency. Reasonably, the inhibitory activity of the novel series could be modulated by
introducing  suitable  substituents  on  the  benzyloxy  nucleus.  Accordingly,  further  investigation  with  both  electron-
withdrawing and electron-donating groups is needed in order to investigate their role in the identification of novel and
more effective ARL2 inhibitors.
All the synthesized compounds, 3-13, were also tested for their ability to inhibit ALR1. Unlike the spiro-derivative
sorbinil, that showed a significant inhibitory activity against ALR1 (IC50 0.029 μM), no inhibition was observed up to
100 μM of  test  compounds (data  not  shown),  thus  our  compounds proved to  be completely  selective for  the  target
ALR2.
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MATERIALS AND METHODS
Chemistry
Melting  points  were  determined  on  a  Kofler  hot-stage  apparatus  and  are  uncorrected.  1H  NMR  spectra  were
obtained with a Varian Gemini 200 MHz spectrometer whereas 13C NMR were obtained with a Bruker TopSpin 3.2 400
MHz spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and
referenced  from  solvent  references.  The  elemental  compositions  of  the  compounds  agreed  to  within  0.4%  of  the
calculated value. Chromatographic separation was performed on silica gel columns by flash (Kieselgel 40, 0.040–0.063
mm; Merck). Reactions were followed by thin layer chromatography (TLC) on Merck aluminum silica gel (60 F254)
sheets  that  were  visualized  under  a  UV lamp.  Evaporation  was  performed  in  vacuo  (rotating  evaporator).  Sodium
sulfate was always used as the drying agent. Commercially available chemicals were purchased from Sigma-Aldrich.
General Procedure for the Synthesis of Compounds 3-13
To a stirred solution of appropriate ester 20-21, 26-29, 32-33, 46-48 (0.77 mmol) in MeOH (3 mL) was added KOH
50% (0.005 mL) and the resulting mixture was refluxed for 2 h. The solvent was evaporated under vacuum and then
HCl 1N was added (pH = 3). The precipitate was filtered and dried.
2-(2-(4-Methoxyphenyl)-2-methyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetic acid3
Compound 3 was obtained from 20 (0.47 g, 1.10 mmol) following procedure previously described without further
purification. 3 (0.09 g, 0.23mmol, yield 21%). Mp175-178°C.1H-NMR (DMSO-d6): δ 1.63 (s, 3H, Me); 2.30 (d, 1H, J =
12.6 Hz, CH2); 2.42 (d, 1H, J = 14.3 Hz, CH2); 2.92 (d, 1H, J = 14.3 Hz, CH2); 3.25 (d, 1H, J = 17.2 Hz, CH2); 3.62 (d,
1H, J = 12.6 Hz, CH2); 3.70 (s, 3H, OMe); 4.16 (d, 1H, J = 17.2 Hz, CH2); 4.22 (d, 1H, J = 17.2 Hz, CH2); 4.35 (d, 1H,
J = 17.2 Hz, CH2); 6.88 (d, 2H, J = 8.7 Hz, Ar); 6.94-7.04 (m, 2H, Ar); 7.26-7.42 (m, 4H, Ar) ppm. 
13C NMR (400
MHz; DMSO-d6): δ 169.83, 166.13, 158.21, 153.34, 136.73, 130.18, 127.68, 125.98, 122.51, 120.68, 116.98, 113.80,
78.04, 68.51, 63.21, 55.30, 55.09, 48.12, 38.42, 29.33 ppm. Anal. (C22H23NO6) C, H, N. % Calcd: 66.49 (C); 5.83 (H);
3.52 (N). % Found: 66.65 (C); 6.00 (H); 3.63 (N).
2-(6-Bromo-2-(4-methoxyphenyl)-2-methyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetic acid4
Compound 4  was obtained from 21  (0.2 g,  0.4 mmol) following the procedure previously described.  The crude
product was purified by crystallization from (iPr)2O to give 4 (0.03 g, 0.07 mmol, yield 18%) 
1HNMR (DMSO-d6): δ
1.64 (s, 3H, Me); 2.30-2.39 (m, 2H, CH2); 2.92 (d, 1H, J = 14.6 Hz, CH2); 3.25-3.38 (m, 2H, CH2); 3.54-3.65 (m, 1H,
CH2); 3.72 (s, 3H, OMe); 4.08-4.40 (m, 2H, CH2); 6.89 (d, 2H, J = 8.8 Hz, Ar); 7.03 (d, 1H, J = 8.6 Hz, Ar); 7.31 (d,
2H, J = 8.8 Hz, Ar); 7.48 (dd, 1H, J = 2.4, 8.6 Hz, Ar); 7.55 (d, 1H, J = 2.4 Hz, Ar) ppm. Anal. (C22H22BrNO6) C, H, N.
Anal. % Calcd: 55.47 (C); 4.66 (H); 2.94 (N). % Found: 55.52 (C); 4.66 (H); 2.94 (N).
2-(2,2-Dimethyl-2'-oxospiro[chroman-4,5'-oxazolidin]-3'-yl) acetic acid5
Compound 5 was obtained from 26 (0.23 g, 0.56 mmol) following procedure previously described without further
purification. 5 (0.04 g, 0.16 mmol, yield 29%). Mp 160-165 °C. 1H-NMR (DMSO-d6): δ 1.32 (s, 3H, Me); 1.36 (s, 3H,
Me); 2.27 (d, 1H, J = 14.8 Hz, CH2); 2.37 (d, 1H, J = 14.8 Hz, CH2); 3.68 (d, 1H, J = 9.1 Hz, CH2); 3.87 (d, 1H, J = 9.1
Hz, CH2); 3.95 (d, 1H, J = 17.7 Hz, CH2); 4.08 (d, 1H, J = 17.7 Hz, CH2); 6.80 (d, 1H, J = 8.7 Hz, Ar); 6.98 (m, 1H,
Ar); 7.26 (m, 1H, Ar); 7.58 (d, 1H, J =8.7 Hz, Ar) ppm. Anal. (C15H17NO5) C, H, N. Anal. % Calcd: 61.85 (C); 5.88 (H);
4.81 (N). % Found: 61.60 (C); 5.85 (H); 4.79 (N).
2-(6-Bromo-2,2-dimethyl-2'-oxospiro[chroman-4,5'-oxazolidin]-3'-yl) acetic acid6
Compound 6 was obtained from 27 (0.33 g, 0.67 mmol) following procedure previously described without further
purification. 6 (0.12 g, 0.35 mmol, 53%yield). Mp165-170°C. 1H-NMR (DMSO-d6): δ 1.32 (s, 3H, Me); 1.36 (s, 3H,
Me); 2.27 (d, 1H, J = 15.0 Hz, CH2); 2.37 (d, 1H, J = 15.0 Hz, CH2); 3.68 (d, 1H, J = 9.2 Hz, CH2); 3.88 (d, 1H, J = 9.2
Hz, CH2); 3.90 (d, 1H, J = 18.1 Hz, CH2); 4.00 (d, 1H, J = 18.1 Hz, CH2); 6.79 (d, 1H, J = 8.7 Hz, Ar); 7.43 (dd, 1H, J =
2.3, 8.7 Hz, Ar); 7.85 (d, 1H, J = 2.3 Hz, Ar) ppm. Anal. (C15H16BrNO5) C, H, N. % Calcd: 48.67 (C); 4.36 (H); 3.78
(N). % Found: 48.3 (C); 4.70 (H); 3.50 (N).
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2-(2,2-Dimethyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetic acid7
Compound  7  was  obtained  from  28  (0.26  g,  0.77  mmol)  following  procedure  previously  described.  The  crude
product was collected without further purification to yield 7 (0.14 g, 0.46 mmol, 60% yield). Mp 163-165°C. 1H-NMR
(CDCl3): δ 1.41 (s, 6H, Me); 2.19 (d, 1H, J = 14.6 Hz, CH2); 2.42 (d, 1H, J = 14.6 Hz, CH2); 3.26 (d, 1H, J = 12.1 Hz,
CH2); 4.02- 4.10 (m, 2H, CH2); 4.35- 4.46 (m, 3H, CH2); 6.84- 7.0 (m, 2H, Ar); 7.22-7.29 (m, 1H, Ar); 7.46- 7.47 (m,
1H, Ar) ppm. 13C NMR (400 MHz; CDCl3): δ 171.88, 168.30, 153.95, 130.58, 127.53, 121.34, 120.95, 118.42, 74.46,
69.43, 63.42, 57.81, 48.10, 39.65, 26.19 ppm. Anal. (C16H19NO5) C, H, N. % Calcd: 62.94 (C); 6.27 (H); 4.59 (N). %
Found: 62.40 (C); 5.83 (H); 4.09 (N).
2-(6-Bromo-2,2-dimethyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetic acid8
Compound 8 was obtained from 29 (0.39 g, 0.96 mmol) following the general procedure. The crude product was
collected without further purification to yield 8 (0.12 g, 0.32 mmol, 34% yield). Mp 132-134°C. 1H-NMR (DMSO-d6):
δ 1.32 (s, 3H, Me); 1.35 (s, 3H, Me); 2.14 (d, 1H, J = 15.0 Hz, CH2); 2.42- 2.52 (m, 1H, CH2); 3.96- 4.24 (m, 6H, CH2);
6.79 (d, 1H, J = 8.7 Hz, Ar); 7.40 (dd, 1H, J = 2.4, 8.7 Hz, Ar); 7.60 (d, 1H, J = 2.4 Hz, Ar) ppm. Anal. (C16H18BrNO5)
C, H, N. % Calcd: 50.02 (C); 4.72 (H); 3.65 (N). % Found: 49.00 (C); 4.18 (H); 2.58 (N).
2-(2,2-Dimethylspiro[chroman-4,2'-morpholin]-4'-yl) acetic acid9
Compound  9  was  obtained  from  32  (0.55  g,  1.90  mmol)  following  procedure  previously  described.  The  crude
product was collected and purified by precipitation from CHCl3/n-Hexane to yield 9 (0.01 g, 0.04 mmol, yield 2%). 
1H-
NMR (CD3OD-d4): δ 1.35 (s, 3H, Me); 1.45 (s, 3H, Me); 2.20 (d, 1H, J = 14.8 Hz, CH2); 2.65 (d, 1H, J = 14.8 Hz,
CH2); 3.26-3.40 (m, 2H, CH2); 3.70-4.01 (m, 3H, CH2); 4.07-4.24 (m, 1H, CH2); 4.90 (s, 2H, CH2); 6.78- 6.83 (m, 1H,
Ar); 6.93- 7.00 (m, 1H, Ar); 7.20- 7.28 (m, 1H, Ar); 7.55 (dd, 1H, J = 1.5, 7.9 Hz, Ar) ppm. Anal. (C16H21NO4) C, H, N.
% Calcd: 65.96 (C); 7.27 (H); 4.81 (N). % Found: 65.69 (C); 7.24 (H); 4.79 (N).
2-(6-Bromo-2,2-dimethylspiro[chroman-4,2'-morpholin]-4'-yl) acetic acid10
Compound 10 was obtained from 33 (0.03 g, 0.11 mmol) and chloroacetic acid (0.01 g, 0.11 mmol) following the
general  procedure.  The  crude  was  used  without  further  purification.  10  (0.005  g,0.07  mmol,  yield  67%).  1H-NMR
(CDCl3):  δ  1.33  (s,  3H,  Me);  1.40  (s,  3H,  Me);  2.14  (d,  1H,  J  =  14.5  Hz,  CH2);  2.54  (d,  1H,  J  =  14.5  Hz,  CH2);
2.70-3.00(m, 4H, CH2); 3.19-3.42 (m, 2H, CH2); 3.78-3.84 (m, 1H, CH2); 3.99-4.10 (m,1H, CH2); 6.71 (d, 1H, J = 8.8
Hz, Ar); 7.29 (dd, 1H, J  = 2.4, 8.8 Hz, Ar); 7.64(d, 1H, J  = 2.4 Hz, Ar) ppm. Anal.  (C16H20BrNO4) C, H, N. Anal.
(C16H21NO4) C, H, N. % Calcd: 51.90 (C); 5.44 (H); 3.78 (N). % Found: 51.74 (C); 5.42 (H); 3.76 (N).
2-(5-(2-((3-Methoxybenzyl)oxy)phenyl)-5-methyl-2-oxooxazolidin-3-yl)acetic acid11
Compound 11  was obtained from 46  (0.05 g,  0.12 mmol)  following procedure previously described.  The crude
product was collected and purified by precipitation from EtOAc/n-Hexane to yield 11 (0.02 g, 0.06 mmol, 49% yield).
Mp117-119 °C. 1H-NMR (CDCl3): δ 1.75 (s, 3H, Me); 3.67-3.79 (m, 2H, CH2); 3.83 (s, 3H, OMe); 4.02-4.11 (m, 2H,
CH2); 5.00 (s, 2H, CH2); 6.91-7.02 (m, 4H, Ar); 7.24-7.32 (m, 3H, Ar); 7.58 (dd, 1H, J = 1.8, 8.1 Hz, Ar) ppm. Anal.
(C20H21NO6) C, H, N. % Calcd: 64.68 (C); 5.70 (H); 3.77 (N). % Found: 64.98 (C); 5.84 (H); 3.57 (N).
2-(5-(2-((3,5-Dimethoxybenzyl)oxy)phenyl)-5-methyl-2-oxooxazolidin-3-yl)acetic acid12
Compound 12 was obtained from 47 (0.05 g, 0.12 mmol) following same procedure described above. The crude was
used without further purification. 12 (0.04 g, 0.11 mmol, 90% yield). Mp118-120 °C. 1H-NMR (CDCl3): δ 1.79 (s, 3H,
Me); 3.65-3.90 (m, 5H, CH2, OMe); 4.03-4.17 (m, 2H, CH2); 4.94-5.08 (m, 2H, CH2); 6.83-7.04 (m, 5H, Ar); 7.26-7.33
(m, 1H, Ar); 7.59-7.63 (m, 1H, Ar) ppm. Anal. (C21H23NO7) C, H, N. % Calcd: 62.83 (C); 5.78 (H); 3.49 (N). % Found:
63.02 (C); 5.67 (H); 3.44 (N).
2-(5-Methyl-2-oxo-5-(2-((3,4,5-trimethoxybenzyl)oxy)phenyl)oxazolidin-3-yl)acetic acid13
Compound  13  was  obtained  from 48  (0.54g,  1.18  mmol)  following  procedure  previously  described.  The  crude
product was dissolved in EtOAc and washed with NaHCO3 and then extracted with CH2Cl2. The organic layers were
dried and concentrated under vacuum to give 13 (0.07 g, 0.15 mmol, 13% yield).1H-NMR (CDCl3): δ 1.83 (s, 3H, Me);
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3.57-4.18 (m,  7H,  CH2,  OMe);  5.02 (s,  2H,  CH2);  6.61 (s,  2H,  Ar);  6.95-7.05 (m,  2H,  Ar);  7.26-7.34 (m,  1H,  Ar);
7.59-7.63 (m, 1H, Ar) ppm. 13C NMR (400 MHz; CDCl3): δ 171.92, 157.54, 154.16, 153.58, 137.83, 132.12, 131.37,
129.41, 125.79, 121.33, 112.05, 105.19, 80.66, 70.46, 61.03, 57.43, 56.27, 44.95, 27.15 ppm. Anal. (C22H25NO8) C, H,
N. % Calcd: 61.25 (C); 5.84 (H); 3.25 (N). % Found: 61.06 (C); 5.82 (H); 3.24 (N).
General Procedure for Synthesis of Compounds 6-17
A solution of NaOH (0.19 g, 4.75 mmol) in H2O (8.5 mL) was added to a solution appropriate amine 14-15 (4.00
mmol) [12] in CH2Cl2 (12 mL). The mixture was stirred, cooled to 0° C and treated dropwise with chloroacetyl chloride
(0.73 g,  6.5  mmol).  At  the end of  the addiction,  the mixture  was stirred vigorously at  r.t.  for  1  h.  The layers  were
separated and the CH2Cl2 solution was washed with diluted HCl and H2O, dried and evaporated.
2-Chloro-N-((4-hydroxy-2-(4-methoxyphenyl)-2-methylchroman-4-yl)methyl)acetamide16
Compound 16 was obtained from 14 (1.6 g, 5.35 mmol) and chloroacetyl chloride (0.86 g, 7.49 mmol) following the
general procedure. The crude product was directly used in the next step without further purification. 16 (1.30 g, 3.47
mmol, yield 65%).1H-NMR (CDCl3): δ 1.67 (s, 3H, Me); 2.29 (d, 1H, J = 14.2 Hz, CH2); 2.63 (d, 1H, J = 14.2 Hz,
CH2); 3.45 (dd, 1H, J = 5.8, 14.4 Hz, CH2); 3.74 (d, 1H, J = 14.4 Hz, CH2); 3.75 (s, 3H, OMe); 3.99 (d, 1H, J = 15.5 Hz,
CH2); 4.09 (d, 1H, J = 15.5 Hz, CH2); 6.79-6.90 (m, 3H, Ar); 6.94-7.02 (m, 1H, Ar); 7.18-7.36 (m, 3H, Ar); 7.45 (d, 1H,
J = 7.6 Hz, Ar) ppm.
N-((6-Bromo-4-hydroxy-2-(4-methoxyphenyl)-2-methylchroman-4-yl)methyl)-2-chloroacetamide17
Compound 17 was obtained from 15 (0.8 g, 2.11 mmol) and chloroacetyl chloride (0.34 g, 2.95 mmol) following the
general procedure. The crude product was directly used in the next step without further purification. 17 (0.8 g, 1.76
mmol, yield 47%). 1H-NMR (CDCl3): δ 1.69 (s, 3H, Me); 2.24-2.36 (m, 2H, CH2); 2.66 (d, 1H, J = 14.2 Hz, CH2);
3.38-3.48 (m, 1H, CH2); 3.78 (s, 3H, OMe); 4.03 (d, 1H, J = 15.7 Hz, CH2); 4.13 (d, 1H, J = 15.7 Hz, CH2); 6.80-6.94
(m, 3H, Ar); 7.24-7.38 (m, 3H, Ar); 7.61 (d, 1H, J = 2.6 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds18-19
Potassium tert-butoxide (1.45 g,  13 mmol) was added portion wise over 1 h to a stirred solution of appropriate
alcohol 16-17  (2.5 mmol) in toluene (20 mL). The reaction mixture was stirred at r.t.  for 2 h, then the solvent was
evaporated. The residue was diluted with EtOAc and the organic layer washed with water, dried and evaporated.
2-(4-Methoxyphenyl)-2-methylspiro[chroman-4,2'-morpholin]-5'-one18
Compound 18 was obtained from 16 (1.30 g, 3.47 mmol) following the procedure previously described. The crude
product was directly used in the next step without further purification. 18 (0.73 g, 2.16 mmol, yield 63%). 1H-NMR
(CDCl3): δ 1.72 (s, 3H, Me); 2.24 (d, 1H, J = 12.8 Hz, CH2); 2.33 (d, 1H, J = 13.7 Hz, CH2); 3.01 (d, 1H, J = 13.7 Hz,
CH2); 3.33 (d, 1H, J = 12.8 Hz, CH2); 3.76 (s, 3H, OMe); 4.38 (s, 2H, CH2); 6.80 (d, 2H, J = 7.6 Hz, Ar); 6.92-6.99 (m,
1H, Ar); 7.03-7.07 (m, 1H, Ar); 7.15-7.39 (m, 4H, Ar) ppm.
6-Bromo-2-(4-methoxyphenyl)-2-methylspiro[chroman-4,2'-morpholin]-5'-one19
Compound 19 was obtained from 17 (0.8 g, 1.76 mmol) following the procedure previously described. The crude
product was directly used in the next step without further purification. 19  (0.63 g, 1.5 mmol, yield 85%). 1H-NMR
(CDCl3): δ 1.74 (s, 3H, Me); 2.29 (d, 1H, J = 12.8 Hz, CH2); 2.35 (d, 1H, J = 13.7 Hz, CH2); 3.05 (d, 1H, J = 13.7 Hz,
CH2); 3.40 (d, 1H, J = 12.8 Hz, CH2); 3.78 (s, 3H, OMe); 4.40 (s, 2H, CH2); 6.82 (d, 2H, J = 8.8 Hz, Ar); 7.03 (d, 1H, J
= 8.6 Hz, Ar); 7.29-7.35 (m, 2H, Ar); 7.45-7.50 (m, 1H, Ar); 7.55 (d, 1H, J = 2.4 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds 20-21, 26-29
To a stirred solution of NaH (0.07 g, 3.00 mmol, 60% dispersion in mineral oil) in dry DMF (10 mL) was added the
appropriate derivatives 18-19, 22-25 (4.00 mmol) under N2 atmosphere. After 30 min, the reaction mixture was cooled
at 0 °C and ethyl bromoacetate (0.83 g, 5.00 mmol) was added. The reaction mixture was allowed to warm at 25 °C and
stirred for 1h before being quenched with water and extracted with EtOAc. The combined organic layers were dried,
filtered, and concentrated under vacuum.
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Ethyl 2-(2-(4-methoxyphenyl)-2-methyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetate20
Compound 20 was obtained from 18 (0.73 g, 2.16 mmol) and ethyl bromoacetate (0.78 g, 2.16 mmol) following the
general procedure. The crude product was purified by flash column chromatography eluting n-Hexane/EtOAc (1:1) to
give 20 (0.47 g, 1.10 mmol, yield 51%): 1H-NMR (CDCl3): δ 1.26 (t, 3H, J = 7.1 Hz, Me); 1.73 (s, 3H, Me); 2.21 (d,
1H, J = 12.6 Hz, CH2); 2.39 (d, 1H, J = 14.2 Hz, CH2); 3.04 (d, 1H, J = 14.2 Hz, CH2); 3.18 (d, 1H, J = 17.3 Hz, CH2);
3.64 (d, 1H, J = 12.6 Hz, CH2); 3.78 (s, 3H, OMe); 4.16 (q, 2H, J = 7.1 Hz, CH2); 4.34 (d, 1H, J = 17.3 Hz, CH2); 4.41
(s, 2H, CH2); 6.82 (d, 2H, J = 8.7 Hz, Ar); 6.93-7.08 (m, 2H, Ar); 7.21-7.36 (m, 3H, Ar); 7.44 (dd, 1H, J = 8.7, 1.4 Hz,
Ar) ppm.
Ethyl 2-(6-bromo-2-(4-methoxyphenyl)-2-methyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetate21
Compound 21 was obtained from 19 (0.3 g, 0.72 mmol) and ethyl bromoacetate (0.12 g, 0.72 mmol) following the
general procedure. The crude product was purified by flash column chromatography eluting n-Hexane/EtOAc (1:1) to
give 21 (0.22 g, 0.4 mmol, yield 55%). 1H-NMR (CDCl3): δ 1.30 (t, 3H, J = 7.0 Hz, Me); 1.75 (s, 3H, Me); 2.23 (d, 1H,
J = 12.4 Hz, CH2); 2.40 (d, 1H, J = 13.2 Hz, CH2); 3.01 (d, 1H, J = 13.2 Hz, CH2); 3.15 (d, 1H, J = 17.0 Hz, CH2); 3.61
(d, 1H, J = 12.4 Hz, CH2); 3.78 (s, 3H, OMe); 4.20 (q, 2H, J = 7.0 Hz, CH2); 4.30 (d, 1H, J = 17.0 Hz, CH2); 4.35 (s,
2H, CH2); 6.72 (d, 2H, J = 8.6 Hz, Ar); 6.97 (d, 1H, J = 8.3 Hz, Ar); 7.00 (d, 2H, J = 8.6 Hz, Ar); 7.60 (dd, 1H, J = 2.5,
8.3 Hz, Ar); 7.65 (d, 1H, J = 2.5 Hz, Ar) ppm.
Ethyl 2-(2,2-dimethyl-2'-oxospiro[chroman-4,5'-oxazolidin]-3'-yl) acetate26
Compound  26  was  obtained  from 22(0.44  g,  1.37  mmol)  following  procedure  previously  described.  The  crude
product was directly used for the next reaction without further purification. 26 (0.23 g, 0.56 mmol, yield 41%): 1H-
NMR (CDCl3): δ 1.33 (t, 3H, J =7.1 Hz, Me); 1.42 (s, 6H, Me); 2.17 (d, 1H, J =14.6 Hz, CH2); 2.46 (d, 1H, J =14.6 Hz,
CH2); 3.64 (d, 1H, J =8.4 Hz, CH2); 3.98 (d, 1H, J =8.4 Hz, CH2); 4.02 (d, 1H, J =18.0 Hz, CH2); 4.20 (d, 1H, J =18.0
Hz, CH2); 4.25 (q, 2H, J =7.1 Hz, CH2); 6.82 (d, 1H, J =8.2 Hz, Ar); 6.94-7.02 (m, 1H, Ar); 7.20-7.29 (m, 1H, Ar); 7.58
(dd, 1H, J =8.0 Hz, Ar) ppm.
Ethyl 2-(6-bromo-2,2-dimethyl-2'-oxospiro[chroman-4,5'-oxazolidin]-3'-yl) acetate27
Compound 27  was obtained from 23  (0.55 g,  1.37 mmol)  following procedure previously described.  The crude
product was directly used for the next reaction without further purification. 27 (0.33 g, 0.67 mmol, yield 49%): 1H-
NMR (CDCl3): δ 1.32 (t, 3H, J = 7.1 Hz, Me); 1.41 (s, 6H, Me); 2.16 (d, 1H, J = 14.7 Hz, CH2); 2.45 (d, 1H, J = 14.7
Hz, CH2); 3.67 (d, 1H, J = 8.7 Hz, CH2); 3.93 (d, 1H, J = 8.7 Hz, CH2); 4.01-4.33 (m, 4H, CH2); 6.70 (d, 1H, J = 8.7 Hz,
Ar); 7.33 (dd, 1H, J= 2.4, 8.7 Hz, Ar); 7.68 (d, 1H, J = 2.4 Hz, Ar) ppm.
Ethyl 2-(2,2-dimethyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetate28
Compound 28 was obtained from 24 (0.6 g, 2.42 mmol) and ethyl bromo acetate (0.48 g, 2.90 mmol) following the
procedure  previously  described.  The  crude  product  was  purified  by  flash  column  chromatography  eluting  n-
Hexane/EtOAc (7:3) to give 27 (0.26 g, 0.77 mmol, yield 32%): 1H-NMR (CDCl3): δ 1.21- 1.41 (m, 9H, Me); 2.21 (d,
1H, J = 14.7 Hz, CH2); 2.42 (d, 1H, J = 14.7 Hz, CH2); 3.22 (d, 1H, J = 12.1 Hz, CH2); 3.93- 4.41 (m, 7H, CH2); 6.84
(dd, 1H, J = 1.4; 8.0 Hz, Ar); 6.90- 6.98 (m, 1H, Ar); 7.19- 7.28 (m, 1H, Ar); 7.49 (dd, 1H, J = 1.4; 8.0 Hz, Ar) ppm.
Ethyl 2-(6-bromo-2,2-dimethyl-5'-oxospiro[chroman-4,2'-morpholin]-4'-yl) acetate29
Compound 29 was obtained from 25 (0.33 g, 1.00 mmol) and ethyl bromo acetate (0.20 g, 1.20 mmol) following the
procedure  previously  described.  The  crude  product  was  purified  by  flash  column  chromatography  eluting  n-
Hexane/EtOAc (7:3) to give 29 (0.18 g, 0.44 mmol, yield 44%) 1H-NMR (CDCl3): δ 1.20-1.41 (m, 9H, Me); 2.20-2.45
(m, 2H CH2); 3.20 (d, 1H, J = 12.2 Hz, CH2); 3.90- 4.44 (m, 7H, CH2); 6.73 (d, 1H, J = 8.7 Hz, Ar); 7.32 (dd, 1H, J =
2.5, 8.7 Hz, Ar); 7.61 (d, 1H, J= 2.5 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds 32-33
To a solution of appropriate derivatives 30-31 (0.57 mmol) in MeCN (5 mL) was added K2CO3 (0.09 g, 0.64mmol)
and ethyl  bromoacetate  (0.09 g,  5.00 mmol).  The resulting mixture  was refluxed for  12 h,  then,  after  cooling,  was
filtered and the solvent evaporated.
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Ethyl 2-(2,2-dimethylspiro[chroman-4,2'-morpholin]-4'-yl) acetate32
Compound 32 was obtained from 30 (0.45 g, 1.92 mmol) and ethyl bromoacetate (0.32 g, 1.92 mmol) following the
same  procedure  described  in  the  general  procedure.  The  crude  product  was  used  for  the  next  step  without  further
purification. 32 (0.55 g, 1.90 mmol, yield 99%): 1H-NMR (CDCl3): δ 1.22-1.33 (m, 3H, Me); 1.36 (s, 3H, Me); 1.41 (s,
3H, Me); 2.28 (d, 1H, J = 14.8 Hz, CH2); 2.56 (d, 1H, J = 14.8 Hz, CH2); 2.65-2.90 (m, 2H, CH2); 3.19 (d, 1H, J = 16.7
Hz, CH2); 3.37 (d, 1H, J = 16.7 Hz, CH2); 3.73-3.82 (m, 3H, CH2); 4.01-4.28 (m, 3H, CH2); 6.78-6.96 (m, 2H, Ar);
7.14-7.23 (m, 1H, Ar); 7.56 (dd, 1H, J = 1.5, 7.8 Hz, Ar) ppm.
Ethyl 2-(6-bromo-2,2-dimethylspiro[chroman-4,2'-morpholin]-4'-yl) acetate33
Compound 33 was obtained from 31 (0.6 g, 2.42 mmol) and ethyl bromoacetate (0.40 g, 2.42 mmol) following the
procedure previously described. The crude product was purified by flash column chromatography eluting n-Hexane/
EtOAc (7:3) to give 33.(0.56 g, 1.98 mmol, yield 97%): 1H-NMR (CDCl3): δ 1.20- 1.30 (m, 3H, Me); 1.33 (s, 3H, Me);
1.39 (s, 3H, Me); 2.25 (d, 1H, J = 14.5 Hz, CH2); 2.56 (d, 1H, J = 14.5 Hz, CH2); 2.67 (d, 1H, J = 10.0 Hz, CH2); 2.93
(d, 1H, J = 10.0 Hz, CH2); 3.19 (d, 1H, J = 16.4 Hz, CH2); 3.37 (d, 1H, J = 16.4 Hz, CH2); 3.69-3.80 (m, 3H, CH2);
3.99-4.11 (m, 3H, CH2); 6.79 (d, 1H, J = 8.7 Hz, Ar); 7.4 (dd, 1H, J = 2.5, 8.7 Hz, Ar); 7.6 (d, 1H, J = 2.5 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds 34-36
To a solution of 2-hydroxyacetophenone (1.5 g, 11.03 mmol) in DMSO (7 mL) was added KOH (1.86 g, 33.09
mmol) and the resulting mixture was stirred at 50°C for 15 min. After cooling to r.t. the appropriate methoxybenzyl
chloride  (11.03  mmol)  was  added.  The  reaction  mixture  was  stirred  at  r.t.  for  4h  and  then  washed  with  H2O and
NaHCO3sat. The organic layer was dried, filtered and evaporated under vacuum.
1-(2-((3-Methoxybenzyl)oxy)phenyl)ethanone34
Compound 34 was synthesized from 2-hydroxyacetophenone (1.5 g, 11.03 mmol) and 4-methoxybenzyl chloride
(1.73 g, 11.03 mmol) following the procedure previously described. The crude product was directly used in the next
step without further purification. 34(1.5 g, 5.83 mmol, yield 53%).1H-NMR (CDCl3): δ 2.57 (s, 3H, Me); 3.83 (s, 3H,
OMe); 5.09 (s, 2H, CH2); 6.93 (d, 2H, J = 8.6 Hz, Ar); 6.96-7.05 (m, 2H, Ar); 7.36 (d, 2H, J= 8.6 Hz, Ar); 7.40-7.49
(m, 1H, Ar); 7.75 (dd, 1H, J = 2.0, 7.7, Hz, Ar) ppm.
1-(2-((3,5-Dimethoxybenzyl)oxy)phenyl)ethanone35
Compound  35  was  synthesised  from  2-hydroxyacetophenone  (1.5  g,  11.03  mmol)  and  3,4-dimethoxybenzyl
chloride (2.06 g, 11.03 mmol) following the same procedure described in general procedure. The crude product was
directly used for the next reaction without further purification. 35 (1.83 g, 9.81 mmol, yield 89%): 1H-NMR (CDCl3): δ
2.59 (s, 3H, Me); 3.89 (s, 3H, OMe); 3.90 (s, 3H, OMe); 5.09 (s, 2H, CH2); 6.85-7.05 (m, 5H, Ar); 7.41-7.49 (m, 1H,
Ar); 7.74 (dd, 1H, J =1.8, 7.5 Hz, Ar) ppm.
1-(2-((3,4,5-Trimethoxybenzyl)oxy)phenyl)ethanone36
Compound  36  was  synthesised  from  2-hydroxyacetophenone  (0.9  g,  6.61  mmol)  and  3,4,5-trimethoxybenzyl
chloride (1.5 g, 6.93 mmol) following the same procedure previously described. The crude product was directly used for
the next reaction without further purification. 36 (1.9 g, 6.03 mmol, yield 87%). 1HNMR (CDCl3): δ 2.63 (s, 3H, Me);
3.86 (s, 9H, OMe); 5.09 (s, 2H, CH2); 6.67 (s, 2H, Ar); 6.99-7.06 (m, 2H, Ar); 7.41-7.50 (m, 1H, Ar); 7.74 (dd, 1H, J =
1.7, 8.0 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds 37-39
To  a  solution  of  appropriate  derivatives  37-39  (1.23  g,  7  mmol)  in  CH2Cl2  was  added  trimethylsilylcyanide
(TMSCN) (1.4 mL, 10.5 mmol) and ZnI2 (0.33 g, 1.05 mmol). The mixture was stirred at r.t. for 4 h, then CH2Cl2 was
added and the solution was washed with water. The organic layer was dried and evaporated.
3-(2-((3-Methoxybenzyl)oxy)phenyl)-3-((trimethylsilyl)oxy)butanenitrile37
Compound 37 was synthesised from 34 (1.5 g, 5.83 mmol) following the procedure described in general procedure.
The  crude  product  was  directly  used  in  the  next  step  without  further  purification.  37  (1.74  g,  4.88  mmol,  yield
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84%).1HNMR (CDCl3): δ 0.31 (s, 9H, Me); 1.89 (s, 3H, Me); 3.82 (s, 3H, OMe); 5.05-5.16 (m, 2H, CH2); 6.77-7.04 (m,
4H, Ar); 7.19-7.35 (m, 1H, Ar); 7.46 (d, 2H, J= 8.8 Hz; Ar); 7.56 (dd, 1H, J = 2.0, 8.8 Hz, Ar) ppm.
3-(2-((3,5-Dimethoxybenzyl)oxy)phenyl)-3-((trimethylsilyl)oxy)butanenitrile38
Compound 38  was synthesised from 35  (1.09 g, 5.83 mmol) following the procedure previously described. The
crude product was directly used in the next step without further purification. 38 (1.91 g, 4.95 mmol, yield 85%): 1H-
NMR (CDCl3): δ 0.29 (s, 9H, Me); 1.89 (s, 3H, Me); 3.89 (s, 3H, OMe); 3.90 (s, 3H, OMe); 5.03-5.18 (m, 2H, CH2);
6.67-7.03 (m, 5H, Ar); 7.18-7.41 (m, 1H, Ar); 7.56 (dd, 1H, J =1.8, 8.1 Hz) ppm.
3-(2-((3,4,5-Trimethoxybenzyl)oxy)phenyl)-3-((trimethylsilyl)oxy)butanenitrile39
Compound 39  was synthesised from 36  (1.90 g, 6.03 mmol) following the same procedure described in general
procedure. The crude product was directly used in the next step without further purification. 39 (2.22 g, 5.37 mmol,
yield 89%).1H-NMR (CDCl3): δ 0.26 (s, 9H, Me); 2.01 (s, 3H, Me); 3.88 (s, 9H, OMe); 5.18 (s, 2H, CH2); 6.80 (s, 2H,
Ar); 7.01-7.08 (m, 2H, Ar); 7.35-7.42 (m, 2H, Ar) ppm.
General Procedure for Synthesis of Compounds 40-42
A solution of appropriate trimethylsilyl cyanohydrins 37-39 (5.00 mmol) in THF was added dropwise at 0°C to a
solution of LiAlH4 (1M in THF, 10 mmol). The reaction mixture was stirred at r.t. for 1h, then quenched with water and
NaOH. The resulting lithium salts were filtered and the solution was evaporated.
1-Amino-2-(2-((3-methoxybenzyl)oxy)phenyl)propan-2-ol40
Compound  40  was  synthesised  from  37  (1.74  g,  4.88  mmol)  following  the  procedure  described  in  the  general
procedure. The crude product was directly used in the next step without further purification. 40 (0.83 g, 2.88 mmol,
yield 59%).1H-NMR (CDCl3): δ 1.49 (s, 3H, Me); 3.31 (d, 1H, J = 12.7 Hz, CH2); 3.51 (d, 1H, J = 12.7 Hz, CH2); 3.83
(s, 3H, OMe); 5.00-5.14 (m, 2H, CH2); 6.87-7.05 (m, 4H, Ar); 7.18-7.28 (m, 1H, Ar); 7.35 (d, 2H, J = 8.6 Hz, Ar); 7.68
(d, 1H, J = 2.0, 8.6Hz, Ar) ppm.
1-Amino-2-(2-((3,5-dimethoxybenzyl)oxy)phenyl)propan-2-ol41
Compound 41 was synthesised from 38 (1.91 g, 4.95 mmol) following the procedure described above. The crude
product was directly used in the next step without further purification. 41 (1.19 g, 3.76 mmol, yield 76%).1H-NMR
(CDCl3): δ 1.54 (s, 3H, Me); 2.77 (d, 1H, J =12.7 Hz, CH2); 3.29 (d, 1H, J =12.7 Hz, CH2); 3.88 (s, 3H, OMe); 3.89 (s,
3H, OMe); 5.03 (s, 2H, CH2); 6.62-7.02 (m, 5H, Ar); 7.20-7.28 (m, 1H, Ar); 7.45-7.50 (m, 1H, Ar) ppm.
1-Amino-2-(2-((3,4,5-trimethoxybenzyl)oxy)phenyl)propan-2-ol42
Compound 42  was synthesised from 39  (1.91 g, 4.95 mmol) following the procedure previously described. The
crude product was directly used in the next step without further purification. 42 (1.21 g, 3.49 mmol, yield 65%) 1H-
NMR (CDCl3): δ 1.57 (s, 3H, Me); 2.80 (d, 1H, J =12.7 Hz, CH2); 3.31 (d, 1H, J=12.7 Hz, CH2); 3.85 (s, 9H, OMe);
5.03 (s, 2H, CH2); 6.65 (s, 2H, Ar); 6.90-7.02 (m, 2H, Ar); 7.18-7.28 (m, 1H, Ar); 7.48-7.53 (m, 1H, Ar) ppm.
General Procedure for Synthesis of Compounds 43-45
A  solution  of  aminoalcohols  40-42(6.33  mmol)  in  THF  was  added  dropwise  to  a  solution  of  N,N’-carbonyl
diimidazole (CDI) (1.02 g, 6.33 mmol) in THF at 0 °C. The reaction mixtures were stirred r.t. for 5h. The solvent was
evaporated under vacuum and the residue diluted with EtOAc and washed with HCl 1N and K2CO3sat. The organic
layers were dried and concentrated under vacuum.
5-(2-((3-Methoxybenzyl)oxy)phenyl)-5-methyloxazolidin-2-one43
Compound 43 was synthesised from 40 (0.48 g, 1.67 mmol) following the general procedure. The crude product
was purified by flash column chromatography eluted by n-Hexane/EtOAc (5.5:4.5) to give 43 (0.16 g, 0.5 mmol, yield
30%): 1H-NMR (CDCl3): δ1.73 (s, 3H, Me); 3.62 (d, 1H, J = 9.1 Hz, CH2); 3.72 (d, 1H, J = 9.1 Hz, CH2); 3.83 (s, 3H,
OMe); 4.99 (s, 2H, CH2); 6.93 (d, 2H, J = 8.4 Hz, Ar); 6.96-7.04 (m, 2H, Ar); 7.25-7.33 (m, 3H, Ar); 7.59-7.63 (m, 1H,
Ar) ppm.
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5-(2-((3,5-Dimethoxybenzyl)oxy)phenyl)-5-methyloxazolidin-2-one44
Compound 44 was synthesised from 41 (0.53 g, 1.67 mmol) following the procedure described above. The crude
product was directly used in the next step without further purification. 44 (0.45 g, 1.30 mmol, yield 78%).1H-NMR
(CDCl3) δ: 1.75 (s, 3H, Me); 3.63 (d, 1H, J = 9.1 Hz, CH2); 3.73 (d, 1H, J = 9.1 Hz, CH2); 3.89 (s, 3H, OMe); 3.90 (s,
3H, OMe); 4.92-5.09 (m, 2H, CH2); 6.70-7.04 (m, 5H, Ar); 7.25-7.33 (m, 1H, Ar); 7.58-7.63 (m, 1H, Ar) ppm.
5-Methyl-5-(2-((3,4,5-trimethoxybenzyl)oxy)phenyl)oxazolidin-2-one45
Compound 45 was synthesised from 42 (1.21 g, 3.49 mmol) following the general procedure. The crude product
was directly used in the next step without further purification. 45 (1.07 g, 2.86 mmol, yield 82%).1H-NMR (CDCl3): δ
1.80 (s, 3H, Me); 3.67-3.93 (m, 11H, CH2, OMe); 4.92-5.45 (m, 2H, CH2); 6.60 (s, 2H, Ar); 6.92-7.06 (m, 2H, Ar);
7.20-7.30 (m, 1H, Ar); 7.62 (dd, 1H, J = 1.6, 7.7 Hz, Ar) ppm.
General Procedure for Synthesis of Compounds46-48
To a stirred solution of NaH (0.07 g, 3.00 mmol, 60% dispersion in mineral oil) in dry DMF (10 mL) was added
appropriate compounds 43-45 (0.9 g, 4.00 mmol) under N2 atmosphere. After 30 min, the reaction mixture was cooled
at 0 °C and ethyl bromoacetate (0.83 g, 5.00 mmol) was added. The reaction mixture was allowed to warm at 25 °C and
stirred for 1 h before being quenched with water and extracted with EtOAc. The combined organic layers were dried,
filtered, and concentrated under vacuum.
Ethyl 2-(5-(2-((3-methoxybenzyl)oxy)phenyl)-5-methyl-2-oxooxazolidin-3-yl)acetate46
Compound 46 was synthesised from 43 (0.16 g, 0.5 mmol) and ethylbromoacetate (0.08 g, 0.5 mmol) following the
procedure described above. The crude product was directly used in the next step without further purification. 46 (0.16 g,
0.4 mmol, yield 81%): 1H-NMR (CDCl3): δ 1.18-1.27 (m, 3H, Me); 1.77 (s, 3H, Me); 3.66-3.78 (m, 2H, CH2); 3.83 (s,
3H, OMe); 4.02-4.26 (m, 4H, CH2); 5.01 (s, 2H, CH2); 6.91-7.04 (m, 4H, Ar); 7.26-7.33 (m, 3H, Ar); 7.59-7.63 (m, 1H,
Ar) ppm.
Ethyl 2-(5-(2-((3,5-dimethoxybenzyl)oxy)phenyl)-5-methyl-2-oxooxazolidin-3-yl)acetate47
Compound 47 was synthesised from 44 (0.17 g, 0.5 mmol) and ethyl bromoacetate (0.08 g, 0.5 mmol) following the
general procedure. The crude product was directly used in the next step without further purification. 47 (0.17 g, 0.4
mmol,  yield  81%).1H-NMR (CDCl3):  δ  1.14-1.33  (m,  3H,  Me);  1.79  (s,  3H,  Me);  3.65-3.98  (m,  10H,  CH2,  OMe);
4.02-4.25  (m,  2H,  CH2);  5.01  (s,  2H,  CH2);  6.70-6.79  (m,  1H,  Ar);  6.83-7.03  (m,  4H,  Ar);  7.24-7.33  (m,  1H,  Ar);
7.58-7.62 (m, 1H, Ar) ppm.
Ethyl 2-(5-methyl-2-oxo-5-(2-((3,4,5-trimethoxybenzyl)oxy)phenyl)oxazolidin-3-yl)acetate48
Compound 48 was synthesised from 45 (0.50 g, 1.34 mmol) and ethyl bromoacetate (0.22 g, 1.34 mmol) following
the procedure previously described. The crude product was directly used in the next step without further purification. 48
(0.54 g, 1.18 mmol, yield 88%).1H-NMR (CDCl3): δ 1.14-1.33 (m, 3H, Me); 1.84 (s, 3H, Me); 3.70-3.92 (m, 13H, CH2,
OMe); 4.06-4.22 (m, 2H, CH2); 4.94-5.17 (m, 2H, CH2); 6.61 (s, 2H, Ar); 6.93-7.05 (m, 2H, Ar); 7.20-7.30 (m, 1H, Ar);
7.63 (dd, 1H, J = 1.6, 7.7 Hz, Ar) ppm.
Biology
Materials and Methods
Adult Sprague-Dawley albino rats (body weights of 120−140), provided by Harlan Nossan, Italy, were exploited to
obtain  the  target  enzymes,  ALR2 and ALR1,  which were  isolated and purified from lens  and kidney,  respectively,
following a previously reported protocol [17 - 19]. Pyridine coenzyme, D,L-glyceraldehyde, and sodium D-glucuronate
came from Sigma-Aldrich while Sorbinil was a gift from Pfizer, Groton CT. All other chemicals were of reagent grade.
Enzymatic Assays
The activity of the two enzymes was determined spectrophotometrically by monitoring the change in absorbance at
340 nm, which is due to the oxidation of NADPH catalyzed by ALR2 and ALR1. The change in pyridine coenzyme
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concentration/min was determined using a Beckman DU-64 kinetics software program (Solf Pack TM Module).
ALR2 activity was determined at 30°C in a reaction mixture containing 10 mM D,L-glyceraldehyde, 0.104 mM
NADPH, 0.1 M sodium phosphate buffer (pH 6.2), deionized water and the enzyme extract, in a total volume of 1 mL.
ALR1  activity  was  assayed  at  37°C  in  a  reaction  mixture  containing  20  mM sodium D-glucuronate,  0.12  mM
NADPH, 0.1 M sodium phosphate buffer (pH 7.2) and the enzyme extract, in a total volume of 1 mL.
Enzymatic Inhibition
The new synthesized compounds were tested for the inhibitory activity against ALR2 and ALR1 by adding 0.1 mL
of the inhibitor solution to the reaction mixture described above. The inhibitors were solubilized in water, and the pH
was adjusted to 7. A reference blank containing all the above assay components except the substrate was prepared, to
correct for the non-enzymatic oxidation of NADPH and for absorption by the compounds tested.
The inhibitory effect of the new derivatives was routinely estimated at a concentration of 10-4 M. Those compounds
found to be active were tested at additional concentrations between 10-5 and 10-7 M. The IC50 values were determined
through linear regression analysis of the log-dose response curve, generated using at least four concentrations of the
inhibitor causing an inhibition between 20% and 80%, with two replicates at each concentration.
CONCLUSION
In  this  study,  we  described  the  design,  synthesis  and  biological  evaluation  of  three  small  series  of
spirooxazolidinone,  spiromorpholinone  and  benzyloxy  acetic  acid  derivatives,  proposed  as  novel  ALR2  inhibitors.
Moving from our previously developed spirochromanes 1 and 2 [12], and through suitable chemical manipulation of
both their substitution pattern and their main heterocyclic structure, we succeeded in obtaining a novel set of analogues
which proved to inhibit the target enzyme showing IC50 values in the micromolar/low micromole range.
According to SARs observed, the presence of a pendant phenyl ring in the 2-position of the central core is essential
to confer a good inhibitory activity to the spirooxazolidine and spiromorpholine derivatives bearing a 6-bromine atom.
On the contrary, a gem-dimethyl substitution proves to be more fruitful in the case of the 6-unsubstituted analogues.
The flexible benzyloxy derivatives benefit from the presence of methoxy groups in suitable positions of the pendant
phenyl ring.
Although further substitution patterns are needed to extend and deepen SARs observed for the three sub-series, the
novel compounds here proposed represent a good starting point for the obtainment of novel and effective ARIs.
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